BR112014029856A2 - formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal - Google Patents

formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal

Info

Publication number
BR112014029856A2
BR112014029856A2 BR112014029856A BR112014029856A BR112014029856A2 BR 112014029856 A2 BR112014029856 A2 BR 112014029856A2 BR 112014029856 A BR112014029856 A BR 112014029856A BR 112014029856 A BR112014029856 A BR 112014029856A BR 112014029856 A2 BR112014029856 A2 BR 112014029856A2
Authority
BR
Brazil
Prior art keywords
amino acid
polypeptide
acid sequence
salt
sequence
Prior art date
Application number
BR112014029856A
Other languages
English (en)
Portuguese (pt)
Inventor
Larche Mark
Hickey Pascal
Laidler Paul
Peter Hafner Roderick
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46582267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014029856(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of BR112014029856A2 publication Critical patent/BR112014029856A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ecology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
BR112014029856A 2012-06-01 2013-05-30 formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal BR112014029856A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209868.7A GB201209868D0 (en) 2012-06-01 2012-06-01 Alternaria peptides
PCT/GB2013/051439 WO2013179043A1 (en) 2012-06-01 2013-05-30 Alternaria peptides

Publications (1)

Publication Number Publication Date
BR112014029856A2 true BR112014029856A2 (pt) 2017-07-25

Family

ID=46582267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029856A BR112014029856A2 (pt) 2012-06-01 2013-05-30 formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal

Country Status (17)

Country Link
US (1) US20150098969A1 (enExample)
EP (1) EP2855515A1 (enExample)
JP (1) JP2015520771A (enExample)
KR (1) KR20150028788A (enExample)
CN (1) CN104507959A (enExample)
AU (1) AU2013269326A1 (enExample)
BR (1) BR112014029856A2 (enExample)
CA (1) CA2875130A1 (enExample)
CL (1) CL2014003290A1 (enExample)
EA (1) EA201492268A1 (enExample)
GB (2) GB201209868D0 (enExample)
HK (1) HK1201752A1 (enExample)
IL (1) IL235840A0 (enExample)
IN (1) IN2014DN10558A (enExample)
MX (1) MX2014014461A (enExample)
SG (1) SG11201407975TA (enExample)
WO (1) WO2013179043A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160130311A1 (en) * 2013-06-05 2016-05-12 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400723B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
JP2007176953A (ja) * 1996-03-10 2007-07-12 Meiji Milk Prod Co Ltd アレルギー疾患に対するペプチド免疫療法剤
JP2003116556A (ja) * 2001-10-09 2003-04-22 Nippon Zenyaku Kogyo Kk アレルギー性皮膚炎治療剤
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CN103272227B (zh) * 2007-08-15 2014-12-10 切尔卡西亚有限公司 针对过敏原去敏化的肽
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20130259884A1 (en) * 2010-09-24 2013-10-03 Alergenetica Sl Peptides

Also Published As

Publication number Publication date
KR20150028788A (ko) 2015-03-16
CN104507959A (zh) 2015-04-08
US20150098969A1 (en) 2015-04-09
SG11201407975TA (en) 2015-01-29
MX2014014461A (es) 2015-02-10
EP2855515A1 (en) 2015-04-08
GB201209868D0 (en) 2012-07-18
JP2015520771A (ja) 2015-07-23
WO2013179043A1 (en) 2013-12-05
HK1201752A1 (en) 2015-09-11
IL235840A0 (en) 2015-01-29
CL2014003290A1 (es) 2015-05-22
GB2517871A (en) 2015-03-04
IN2014DN10558A (enExample) 2015-08-21
AU2013269326A1 (en) 2014-12-18
EA201492268A1 (ru) 2015-05-29
CA2875130A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
PE20080397A1 (es) Proteinas de fusion del receptor de productos finales de glicacion avanzada (ragepor sus sigla en ingles), formulaciones, y metodos de uso de las mismas
MX2016016063A (es) Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
AR071756A1 (es) Agente para el tratamiento y/o la prevencion de una enfermedad autoinmune y para la formacion de celulas t reguladoras. procedimientos.
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
MX2012002216A (es) Nueva endolisina obpgplys.
BR112014023374A2 (pt) composições de peptídeos de glp-1 e preparação das mesmas
EA201490393A1 (ru) Соматотропный гормон пролонгированного действия и способы его получения
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
PE20241305A1 (es) Analogos de amilina
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
MX2020005326A (es) Formulaciones que contienen linaclotida para administracion oral.
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
MX378431B (es) Uso terapèutico de proteìnas morfogenèticas òseas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]